| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
34 |
| Employees |
22 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-26 |
| Cash Flow (TTM) (Millions $) |
-74 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Imago Biosciences Inc is a privately held biotechnology company located in California, USA. The company was founded in 2013 by three experienced scientific and business professionals, Hugh Young Rienhoff Jr., Mark G. Lackner, and David A. Mott. Imago Biosciences focuses on developing innovative therapies for the treatment of cancers and other diseases that have limited treatment options.
The company has developed a proprietary drug discovery platform that is designed to identify and develop novel therapeutic compounds to target specific disease pathways. The platform utilizes a unique approach to drug discovery that involves identifying small molecules that bind to a specific protein of interest. Once a promising drug candidate is identified, Imago Biosciences uses a series of rigorous pre-clinical and clinical trials to evaluate its potential efficacy, safety, and tolerability.
The company's lead drug candidate is called IMG-7289, a small molecule inhibitor that targets the lysine-specific demethylase 1 (LSD1) protein. LSD1 is an enzyme that plays a critical role in cancer cell proliferation and survival. Preclinical studies have demonstrated that IMG-7289 can effectively inhibit LSD1 activity and induce apoptosis in cancer cells, leading to potential therapeutic benefits for patients with various types of cancer.
Imago Biosciences is also developing other drug candidates for the treatment of cancer, fibrosis, and other diseases. In addition, the company has established collaborations with leading academic and research institutions to accelerate drug discovery and development.
The team at Imago Biosciences is made up of seasoned professionals with extensive experience in drug discovery, development, and commercialization. The company's leadership team includes scientific and business professionals with decades of experience in the biotech industry.
Overall, Imago Biosciences is a promising biotech startup that is focused on developing innovative therapies for cancer and other diseases with limited treatment options. With its proprietary drug discovery platform, strong leadership team, and growing pipeline of drug candidates, the company is well-positioned to make a significant impact in the biotech industry.
Company Address: 303 Twin Dolphin Drive Redwood City 94065 CA
Company Phone Number: 529-5055 Stock Exchange / Ticker: NASDAQ IMGO
|
%